Article
Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients.
PloS one - 1 Jan 2023
Pearson Stella, Blance Rognvald, Yan Fei, Hsieh Ya-Ching, Geary Bethany, Amaral Fabio M R, Somervaille Tim C P, Kirschner Kristina, Whetton Anthony D, Pierce Andrew
Abstract excerpt
Myelofibrosis is a myeloproliferative neoplasm (MPN) which typically results in reduced length and quality of life due to systemic symptoms and blood count changes arising from fibrotic changes in the bone marrow. While the JAK2 inhibitor ruxolitinib provides some clinical benefit, there remains a substantial unmet need for novel targeted therapies to better modify the disease process or eradicate the cells at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.